( KOS Greece--(BUSINESS WIRE)--Jun 26 2...)ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical,Model,Health

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results demonstrating that ACE-011, a novel anabolic bone agent for the treatment of bone loss, preserved bone mass and architecture in a murine model of multiple myeloma. Multiple myeloma is a malignancy of plasma cells in the bone marrow that disrupts normal bone marrow function resulting in fractures, vertebral compressions and bone pain. The data were presented today at the 11th International Myeloma Workshop in Kos, Greece.

"The positive results from this study support the growing body of evidence that ACE-011 is a novel bone anabolic agent and may be the first anabolic agent for the treatment of cancer-related bone loss in diseases such as multiple myeloma", said Jasbir Seehra, Ph.D., Chief Scientific Officer at Acceleron.

In the study conducted by Professor Peter Croucher, Ph.D. at the University of Sheffield (UK), mice treated with ACE-011 maintained their bone mass, while untreated mice developed substantial bone loss as a result of the myeloma. Histomorphometry analysis revealed that mice treated with ACE-011 had normal bone formation parameters, while untreated mice had reduced bone formation and increased bone resorption. Furthermore, ACE-011 preserved the number of osteoblasts, the cells responsible for forming new bone, compared to untreated mice which lost these vital bone-forming cells.

"Anti-resorptive agents are current standard of care for multiple myeloma patients yet significant unmet medical need remains as patients continue to experience serious clinical complications such as bone pain and fractures", said Matthew L. Sherman, M.D., Chief Medical Officer at Acceleron. "We are excited by the encouraging results in this preclinical model of multiple myeloma as we prep
'"/>

Page: 1 2 3
Related medicine technology :

1. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
2. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
3. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
4. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
5. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
6. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
7. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
10. Once Daily, Extended-Release Ropinirole Improves Parkinsons Symptoms in Patients not Optimally Controlled With Levodopa
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia